The future of Idogen AB hangs in the balance with the Swedish firm's critical financial situation leaving its lead clinical-stage development program IDO 8 for hemophilia in limbo.
Idogen's announcement on 28 April that its "work with capitalization has not yet produced the desired result" is quite an...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?